IP Library › Granted Patent US 11,865,190
Granted Patent B2
US 11,865,190 · App. 17/941,669 · Granted Jan 9, 2024

Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto

Inventors: Blair Leavitt (Vancouver, CA); Pieter Cullis (Vancouver, CA); Terri Petkau (Vancouver, CA); Austin Hill (Vancouver, CA); Pamela Wagner (Vancouver, CA); Jayesh Kulkarni (Vancouver, CA)
Assignee: THE UNIVERSITY OF BRITISH COLUMBIA
A61K48/0091A61K9/1272A61K9/1277A61K31/7105A61K38/465A61K47/10A61K47/18A61K47/186A61K47/24A61K47/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,865,190
App. No.
17/941,669
Granted
Jan 9, 2024
Kind
B2
Abstract

Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.

Claims (6)

1. A composition comprising at least one cargo entrapped in a lipid-based transfection competent vesicle (TCV), wherein:

(a) the lipid-based TCV consists of 1,2-Dioleyloxy-3-dimethylamino-propane (DODMA) at 20-30 mol %, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) at 20-30 mol %, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) at 10 mol %, and cholesterol at 40 mol %; and

(b) the at least one cargo comprises a Cas9 protein and a guide RNA.

2. The composition of claim 1 , wherein the composition comprises a water-based solution, optionally wherein the water-based solution comprises a 25 mM to 100 mM acetate buffer and/or is pH4.

3. The composition of claim 1 , wherein the lipid-based TCV consists of

DODMA/DOPE/DSPC/cholesterol, respectively at 20/30/10/40 mol %.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2023
From: LEAVITT, BLAIR; CULLIS, PIETER; PETKAU, TERRI; HILL, AUSTIN; WAGNER, PAMELA; KULKARNI, JAYESH
To: THE UNIVERSITY OF BRITISH COLUMBIA
Reel/Frame 065633/0440 →
Continuity (3)
Division 17281678
Provisional Application 62743116 · Oct 9, 2018
Related Publication 20230073819A1 · Mar 9, 2023
Cited By (3)
US 12,559,450 US 12,605,464 US 12,721,909